Unpacking Averages: Assessing FDA's Performance Categorizing

Unpacking Averages: Assessing FDA's Performance Categorizing New Diagnostic Tests Under CLIA | Epstein Becker & Green

This month’s post focuses on how timely FDA decisions are in categorizing new diagnostics under the Clinical Laboratory Improvements Amendments of 1988 (CLIA). The answer is that, on...

Related Keywords

, Clinical Laboratory Improvements Amendments , Epstein Becker , Effective Date ,

© 2025 Vimarsana